GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » 3-Year FCF Growth Rate

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) 3-Year FCF Growth Rate : -16.90% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co 3-Year FCF Growth Rate?

Staidson (Beijing) Biopharmaceuticals Co's Free Cash Flow per Share for the three months ended in Mar. 2024 was ¥-0.06.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -16.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Staidson (Beijing) Biopharmaceuticals Co was 308.20% per year. The lowest was -142.20% per year. And the median was -1.55% per year.


Competitive Comparison of Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate falls into.



Staidson (Beijing) Biopharmaceuticals Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Staidson (Beijing) Biopharmaceuticals Co  (SZSE:300204) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Staidson (Beijing) Biopharmaceuticals Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Business Description

Traded in Other Exchanges
N/A
Address
Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Executives
Zhang Hong Shan Supervisors
Zheng Hong Supervisors
Cheng Jiang Hong Executives
Feng Yu Jing Executives
Ma Li Na Secretary, Director
Zhou Zhi Wen Director
Wang Huan Securities Affairs Representative
Zhang Rong Qin Executives
Xu Jiang Ping Executives
Cao Hai Yan Supervisors
Sun Yan Fang Executives
Jiang Li Xin Director
Gu Jian Ping Director
Xu Xiang Qing Supervisors
Gu Zhen Qi Director

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Headlines

No Headlines